|Bid||12.58 x 2900|
|Ask||12.60 x 800|
|Day's Range||12.23 - 12.81|
|52 Week Range||4.35 - 18.38|
|Beta (3Y Monthly)||2.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.55|
If management could get that cash burn under control, even a little competition wouldn’t stop this firm. And this past quarter, we got confirmation that the management team had done just that.
SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians and Invitae (NVTA), one of the fastest growing genetics companies. The findings support broadening and simplifying current guidelines to ensure all breast cancer patients have access to genetic information to guide their breast cancer care, potential screening for other cancers, and inform their family's health.
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
ATLANTA, Nov. 14, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NVTA), one of the fastest growing genetics companies, are presenting research at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that further underscores the frequency of medically actionable genetic variants and their utility in clinical care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence in the field of genetic counseling. Currently, the American College of Medical Genetics and Genomics (ACMG) recommends reporting clinically significant genetic variants in 59 genes as secondary findings for individuals who undergo whole exome or whole genome sequencing, regardless of the original indication for testing.
Invitae Corp. (NVTA) is a genetic testing company based in San Francisco, whose stated aim is to aggregate the large number of different genetic tests currently available to patients into one single service. It is currently trading around $12.50 per share and has a market capitalization of $970 million. The company's value proposition is to decrease the costs of obtaining and using genetic information for both doctors and patients.
The fast-growing leader in genetic testing soared past a $1 billion market cap in September. Investors reconsidered prior to the release of third-quarter 2018 earnings.
Invitae (NVTA) delivered earnings and revenue surprises of 4.26% and 8.59%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Francisco-based company said it had a loss of 45 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
-- Raising annual volume and revenue guidance amid strong performance -- -- Q3 2018 gross profit of $16.9M up from nearly $5.0M in Q3 2017 -- -- Management hosting conference call and webcast today at ...
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing at no cost to patients through the Alnylam Act® program for individuals who may carry gene mutations associated with primary hyperoxaluria, an ultra-rare genetic disorder affecting the kidneys that most often presents in childhood. The Alnylam Act® program was developed to reduce barriers to genetic testing and counseling in order to help people make informed decisions about their health.
SAN FRANCISCO , Oct. 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results ...
SAN DIEGO, Oct. 17, 2018 /PRNewswire/ -- Researchers from Invitae Corporation (NVTA), one of the fastest growing genetics companies, will present findings showing proactive genetic testing identifies medically significant findings for 16.5 percent of healthy individuals. The data add to a growing body of evidence showing expanding clinical genetic testing to people without identified risks could be beneficial. The platform presentation is among the company's data being presented this week at The American Society of Human Genetics (ASHG) annual meeting in San Diego.
Invitae Corporation (NYSE:NVTA), a US$1.26b small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population andRead More...
SAN FRANCISCO, Sept. 18, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. Eastern / 6:00 a.m. Pacific in New York City. Invitae Corporation (NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.
SAN FRANCISCO, Sept. 11, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, announced the appointment of Chitra Nayak to its Board of Directors, effective September 10, 2018. "We are pleased to welcome Chitra Nayak to our board of directors and look forward to working with her, taking full advantage of her considerable track record of helping companies achieve transformational growth to scale and innovate globally," said Sean George, co-founder and chief executive officer of Invitae. "Chitra has deep operational and commercial leadership expertise in growing market share and strengthening industry leadership positions for rapidly growing companies, including organizations like ours that are transforming highly competitive industries.
On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99. It hit its 52-week high of $12.75 on August 24. For the week ended August 24, Invitae stock closed at $12.56, which represents a ~23% rise from its prior week’s close of $10.21 on August 17. Invitae delivered solid growth in the second quarter of 2018 when it reported revenues of $37.3 million compared to $14.3 million in Q2 2017.